NZ703137A - Cells for producing recombinant iduronate-2-sulfatase - Google Patents

Cells for producing recombinant iduronate-2-sulfatase

Info

Publication number
NZ703137A
NZ703137A NZ703137A NZ70313713A NZ703137A NZ 703137 A NZ703137 A NZ 703137A NZ 703137 A NZ703137 A NZ 703137A NZ 70313713 A NZ70313713 A NZ 70313713A NZ 703137 A NZ703137 A NZ 703137A
Authority
NZ
New Zealand
Prior art keywords
recombinant
cells
protein
sulfatase
cell
Prior art date
Application number
NZ703137A
Other languages
English (en)
Inventor
Ferenc Boldog
Michael Heartlein
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Priority to NZ734670A priority Critical patent/NZ734670A/en
Publication of NZ703137A publication Critical patent/NZ703137A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/99—Oxidoreductases acting on sulfur groups as donors (1.8) with other acceptors (1.8.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NZ703137A 2012-06-29 2013-06-28 Cells for producing recombinant iduronate-2-sulfatase NZ703137A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ734670A NZ734670A (en) 2012-06-29 2013-06-28 Cells for producing recombinant iduronate-2-sulfatase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666719P 2012-06-29 2012-06-29
PCT/US2013/048571 WO2014005019A2 (en) 2012-06-29 2013-06-28 Cells for producing recombinant iduronate-2-sulfatase

Publications (1)

Publication Number Publication Date
NZ703137A true NZ703137A (en) 2017-08-25

Family

ID=49778522

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ703137A NZ703137A (en) 2012-06-29 2013-06-28 Cells for producing recombinant iduronate-2-sulfatase
NZ734670A NZ734670A (en) 2012-06-29 2013-06-28 Cells for producing recombinant iduronate-2-sulfatase

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ734670A NZ734670A (en) 2012-06-29 2013-06-28 Cells for producing recombinant iduronate-2-sulfatase

Country Status (27)

Country Link
US (3) US9150841B2 (enExample)
EP (1) EP2874649B1 (enExample)
JP (3) JP6067849B2 (enExample)
KR (1) KR101710487B1 (enExample)
CN (2) CN107267460A (enExample)
AU (3) AU2013282400B2 (enExample)
BR (1) BR112014032560B1 (enExample)
CA (1) CA2877521C (enExample)
CL (1) CL2014003568A1 (enExample)
CO (1) CO7240394A2 (enExample)
CR (1) CR20140586A (enExample)
DO (1) DOP2014000298A (enExample)
EA (2) EA202090805A1 (enExample)
ES (1) ES2718346T3 (enExample)
GT (1) GT201400302A (enExample)
HK (1) HK1209331A1 (enExample)
IL (3) IL236343A (enExample)
MX (2) MX336716B (enExample)
MY (2) MY157086A (enExample)
NZ (2) NZ703137A (enExample)
PE (1) PE20150957A1 (enExample)
PH (2) PH12016500011B1 (enExample)
SG (2) SG10201509397SA (enExample)
TR (1) TR201904435T4 (enExample)
UA (1) UA118955C2 (enExample)
WO (1) WO2014005019A2 (enExample)
ZA (1) ZA201409396B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3431485B2 (en) 2010-10-01 2024-09-04 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2844737B1 (en) 2012-05-02 2018-03-21 Life Technologies Corporation High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) * 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
US20140004097A1 (en) * 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
EP2885419A4 (en) 2012-08-14 2016-05-25 Moderna Therapeutics Inc ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US9550972B2 (en) 2014-09-29 2017-01-24 General Electric Company Devices, systems and methods for automated cell culturing
EP3101125A1 (en) * 2015-06-05 2016-12-07 Laboratorios Del Dr. Esteve, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
CA3001003A1 (en) 2015-10-05 2017-04-13 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
JP7060235B2 (ja) * 2018-05-18 2022-04-26 国立大学法人広島大学 変異型イズロン酸－２－スルファターゼの機能回復薬剤のスクリーニング方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
CA2185324A1 (en) 1994-03-16 1995-09-21 Steven D. Rosen Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (de) 1995-07-26 1997-01-30 Behringwerke Ag Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen
EP2243827B2 (en) 1996-08-30 2017-11-22 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
EP1179000A4 (en) 1999-02-26 2005-10-12 Millennium Pharm Inc DECISION PROTEINS AND THEIR USE
ATE348173T1 (de) 1999-04-26 2007-01-15 Genentech Inc Zellenzuchtverfahren für glycoproteine
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
JP2003508088A (ja) 1999-09-03 2003-03-04 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５２個のヒト分泌タンパク質
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
JP2004502404A (ja) 2000-02-17 2004-01-29 インサイト・ゲノミックス・インコーポレイテッド ヒトキナーゼ
CA2400638A1 (en) 2000-03-17 2001-09-27 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
AU2002317700A1 (en) 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
JP4319979B2 (ja) 2002-04-26 2009-08-26 ジェネンテック・インコーポレーテッド タンパク質の非アフィニティ精製
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
BR0317723A (pt) 2002-12-23 2005-11-22 Bristol Myers Squibb Co Processo de cultura de células de mamìfero para a produção de proteìna
US8227212B2 (en) 2003-02-11 2012-07-24 Shire Human Genetic Therapies, Inc. Cell that expresses a sulfatase and a formylglycine generating enzyme
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
PL2267024T3 (pl) 2005-06-03 2012-10-31 Ares Trading Sa Wytwarzanie rekombinowanego białka wiążącego IL-18
WO2007108955A1 (en) 2006-03-20 2007-09-27 Medarex, Inc. Protein purification
KR101744142B1 (ko) * 2008-01-18 2017-06-07 바이오마린 파머수티컬 인크. 활성이고 높은 정도로 인산화된 인간 리소좀 술파타아제 효소의 제조 및 그 용도
BR112012007913A2 (pt) * 2009-10-09 2019-09-24 Dow Global Technologies Llc reator adiabático de fluxo pistonado, processo para produzir um prpeno clorado ou fluorado, processo para preparar um produto a jusante e processo para preparar 2,3,3,3-tetrafluoroprop-1-eno (hfo-123yf) ou 1,3,3,3-tetrafluoroprop-1-eno (hfo-123ze)
HUE044865T2 (hu) 2009-10-09 2019-11-28 Armagen Inc Eljárások és készítmények a központi idegrendszerben iduronát-2-szulfatáz-aktivitás növelésére
JPWO2011108451A1 (ja) 2010-03-01 2013-06-27 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
HRP20191924T1 (hr) 2010-06-25 2020-01-10 Shire Human Genetic Therapies, Inc. Postupci i sastavi za isporuku iduronat-2-sulfataze u cns
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제

Also Published As

Publication number Publication date
MX366155B (es) 2019-06-28
US20160053238A1 (en) 2016-02-25
AU2018200710B2 (en) 2019-11-14
IL274266A (en) 2020-06-30
HK1209331A1 (en) 2016-04-01
JP2015521848A (ja) 2015-08-03
MY189314A (en) 2022-02-04
JP2016105737A (ja) 2016-06-16
BR112014032560A2 (pt) 2018-03-06
IL254560A0 (en) 2017-11-30
CO7240394A2 (es) 2015-04-17
EP2874649A4 (en) 2016-05-04
CA2877521A1 (en) 2014-01-03
WO2014005019A3 (en) 2014-02-27
JP6302499B2 (ja) 2018-03-28
KR101710487B1 (ko) 2017-02-27
TR201904435T4 (tr) 2019-05-21
GT201400302A (es) 2019-05-22
PH12014502868A1 (en) 2015-02-23
IL236343A0 (en) 2015-02-26
UA118955C2 (uk) 2019-04-10
CR20140586A (es) 2015-04-06
ES2718346T3 (es) 2019-07-01
EP2874649A2 (en) 2015-05-27
DOP2014000298A (es) 2015-03-31
US20140004593A1 (en) 2014-01-02
CA2877521C (en) 2021-06-01
AU2018200710A1 (en) 2018-02-22
US20180010108A1 (en) 2018-01-11
JP6067849B2 (ja) 2017-01-25
CN104540517A (zh) 2015-04-22
AU2013282400B2 (en) 2016-02-04
JP6755272B2 (ja) 2020-09-16
IL274266B (en) 2021-04-29
PH12014502868B1 (en) 2015-02-23
US9719074B2 (en) 2017-08-01
WO2014005019A2 (en) 2014-01-03
IL236343A (en) 2017-10-31
SG10201509397SA (en) 2015-12-30
PE20150957A1 (es) 2015-07-15
HK1209651A1 (en) 2016-04-08
AU2013282400A1 (en) 2015-01-29
US9150841B2 (en) 2015-10-06
EA202090805A1 (ru) 2020-11-30
MX336716B (es) 2016-01-28
MX2015000189A (es) 2015-04-08
EP2874649B1 (en) 2019-01-02
PH12016500011A1 (en) 2019-08-14
AU2016200460A1 (en) 2016-02-18
KR20150030242A (ko) 2015-03-19
BR112014032560B1 (pt) 2022-04-26
MY157086A (en) 2016-04-19
SG11201408702VA (en) 2015-02-27
JP2018088933A (ja) 2018-06-14
AU2016200460B2 (en) 2017-11-02
CN107267460A (zh) 2017-10-20
ZA201409396B (en) 2018-05-30
NZ734670A (en) 2019-12-20
EA035511B1 (ru) 2020-06-26
CL2014003568A1 (es) 2015-04-24
PH12016500011B1 (en) 2022-07-15
IL254560B (en) 2020-05-31
EA201492183A1 (ru) 2015-06-30

Similar Documents

Publication Publication Date Title
NZ703137A (en) Cells for producing recombinant iduronate-2-sulfatase
MY156588A (en) Systems using cell culture for production of isoprene
AU2018271755A1 (en) Method for culturing natural killer cell, using transformed T cell
CA3003145C (en) Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
SG10201809452RA (en) Cell culture compositions with antioxidants and methods for polypeptide production
SG10201810830UA (en) Cell culture compositions and methods for polypeptide production
MX339769B (es) Sistemas, metodos y composiciones para optimizar injertos enriquecidos con celulas y tejidos.
MX348696B (es) Procesos para la produccion de productos de fermentacion.
PH12014502870A1 (en) Method of producing recombinant iduronate-2-sulfatase
SG10201809901SA (en) Generating Pluripotent Cells De Novo
MX2011013700A (es) Cepa talaromyces y composiciones de enzimas.
MX357280B (es) Método sin alimentadoras para cultivo de células madre espermatogonias de bovino y porcino.
EP2633036A4 (en) DIFFERENTIATION METHOD FOR THE PRODUCTION OF GLIA CELL POPULATIONS
MX369395B (es) Modulacion del crecimiento celular y glucosilacion en la produccion de glucoproteina recombinante.
MY173663A (en) Compositions and methods for biological production of fatty acid derivatives
MX2021009554A (es) Produccion de virus en cultivos celulares.
SG10201901559SA (en) Retinal ganglion cells and progenitors thereof
WO2012074265A3 (ko) 줄기세포의 안정성 증진용 조성물
MY199770A (en) Method for culturing cord blood-derived natural killer cells using transformed t cells
MY161163A (en) Culture medium for human mesenchymal stem cells
MX2024014098A (es) Fabricacion de particulas virales
IL231490B (en) A viral vector containing a plant DNA sequence (codon-optimized) and a method for the temporary production of cholinesterase using this vector
WO2020159963A8 (en) Cell populations with improved production and therapeutic characteristics
MY170408A (en) Process for producing enzymes

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2019 BY ANAQUA SERVICES

Effective date: 20180522

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2020 BY ANAQUA SERVICES

Effective date: 20190521

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2021 BY ANAQUA SERVICES

Effective date: 20200520

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2022 BY ANAQUA SERVICES

Effective date: 20210519

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2023 BY ANAQUA SERVICES

Effective date: 20220523

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2024 BY ANAQUA SERVICES

Effective date: 20230524

ASS Change of ownership

Owner name: TAKEDA PHARMACEUTICAL COMPANY, JP

Effective date: 20231115

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2025 BY ANAQUA SERVICES

Effective date: 20240521

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2026 BY ANAQUA SERVICES

Effective date: 20250521